Alyeska Investment Group
GSK icon

Alyeska Investment Group’s GSK GSK Stock Holding History

Alyeska Investment Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,210,746
Closed -$66.8M – 719
2026
Q1 		$66.8M Buy
1,210,746
+869,118
+254% +$47.1M 0.19% 154
2025
Q4 		$16.8M Buy
+341,628
New +$15.9M 0.05% 335
2025
Q3 		– Sell
-3,156,875
Closed -$121M – 645
2025
Q2 		$121M Buy
3,156,875
+1,420,517
+82% +$54.3M 0.43% 55
2025
Q1 		$67.3M Buy
+1,736,358
New +$63.6M 0.27% 105
2024
Q2 		– Sell
-20,804
Closed -$892K – 607
2024
Q1 		$892K Buy
+20,804
New +$858K 0.01% 418
2019
Q3 		– Sell
-10,811
Closed -$541K – 444
2019
Q2 		$541K Buy
+10,811
New +$542K 0.01% 400

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Alyeska Investment Group's GSK Position: Q2 2026 in Review

Alyeska Investment Group sold out of GSK (GSK) in Q2 2026, closing a stake of 1,210,746 shares — an estimated $66.8M sold.

Alyeska Investment Group first reported a position in GSK in Q2 2019 and held it in 6 quarters. The position peaked at $121M in Q2 2025. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Alyeska Investment Group reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 1,210,746 GSK shares in Q2 2026, an estimated $66.8M.
  • Alyeska Investment Group first reported a position in GSK in Q2 2019 and held it in 6 quarters.
  • Alyeska Investment Group's GSK position peaked at $121M in Q2 2025.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.